Key result
Addition of low-dose or very low-dose spironolactone reduced morning home systolic blood pressure by 8.2 to 13.0 mmHg across patients on CCB, ACEI, or ARB monotherapy.
Why the study?
Does low-dose or very low-dose spironolactone reduce morning home blood pressure in uncontrolled hypertensive patients on monotherapy?
Observational (n=86)
Does low-dose or very low-dose spironolactone reduce morning home blood pressure in uncontrolled hypertensive patients on monotherapy?
Addition of low-dose or very low-dose spironolactone effectively reduces home blood pressure in patients with uncontrolled hypertension on monotherapy, though serum potassium requires monitoring.
May support low-dose spironolactone add-on for home BP control with potassium monitoring; leaves open need for randomized outcome trials.
Low-dose (25 mg) or very low-dose (12.5 mg) spironolactone were added among 86 uncontrolled hypertensive patients who were undergoing monotherapy with calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs), or angiotensin AT1-receptor blockers (ARBs). Morning home systolic/diastolic blood pressure (BP) reduction was similar among the CCB (n = 30, -8.2/-2.6 mmHg), ACEI (n = 22, -13.0/-4.7 mmHg), and ARB (n = 34, -11.5/-5.1 mmHg) groups. An increase in serum potassium correlated positively with the decline in morning systolic BP. Even very low-dose (12.5 mg) spironolactone is clinically effective, although serum potassium should be carefully monitored.
No takes yet. Share an insight, caveat, or question.
Hanazawa et al. (2011) conducted an observational in Essential Hypertension (n=86). Spironolactone was evaluated on Morning home systolic/diastolic blood pressure reduction. Addition of low-dose or very low-dose spironolactone reduced morning home systolic blood pressure by 8.2 to 13.0 mmHg across patients on CCB, ACEI, or ARB monotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: